Difference between revisions of "Bupropion-moclobemide"

From Psychiatrienet
Jump to: navigation, search
Line 9: Line 9:
 
* '''Day 8:''' start moclobemide with 150 mg/day.
 
* '''Day 8:''' start moclobemide with 150 mg/day.
 
* '''Day 12:''' increase moclobemide to 300 mg/day.
 
* '''Day 12:''' increase moclobemide to 300 mg/day.
 +
* '''Day 15:''' if necessary, increase moclobemide to 600 mg/day.
  
  
 
  }}
 
  }}

Revision as of 07:53, 23 July 2009

Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from bupropion to moclobemide.[1] [2]

Nietinrijdenbord.png Stop bupropion
  • Gradually reduce dosage of bupropion to a maximum of 150 mg/ day.
  • When a dosage of 150 mg/day is reached, stop administration.
Eenrichtingbord.png Start moclobemide
  • Day 1-7: wash-out period of one week is necessary.
  • Day 8: start moclobemide with 150 mg/day.
  • Day 12: increase moclobemide to 300 mg/day.
  • Day 15: if necessary, increase moclobemide to 600 mg/day.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.